BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 9932086)

  • 1. [The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan].
    Lavergne O; Bigg DC
    Bull Cancer; 1998 Dec; Spec No():51-8. PubMed ID: 9932086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
    Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
    Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in topoisomerase I-targeting agents, camptothecin analogues.
    Kim DK; Lee N
    Mini Rev Med Chem; 2002 Dec; 2(6):611-9. PubMed ID: 12370044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of topoisomerase I-targeting agents.
    Arbuck SG; Takimoto CH
    Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical applications of the camptothecins.
    Takimoto CH; Wright J; Arbuck SG
    Biochim Biophys Acta; 1998 Oct; 1400(1-3):107-19. PubMed ID: 9748525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Camptothecins: a review of their chemotherapeutic potential.
    Ulukan H; Swaan PW
    Drugs; 2002; 62(14):2039-57. PubMed ID: 12269849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
    Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
    Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
    Jung LL; Zamboni WC
    Drug Resist Updat; 2001 Aug; 4(4):273-88. PubMed ID: 11998845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review camptothecin: current perspectives.
    Li QY; Zu YG; Shi RZ; Yao LP
    Curr Med Chem; 2006; 13(17):2021-39. PubMed ID: 16842195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topoisomerase I inhibitors: review and update.
    Rothenberg ML
    Ann Oncol; 1997 Sep; 8(9):837-55. PubMed ID: 9358934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials using irinotecan.
    Houghton PJ; Santana VM
    J Pediatr Hematol Oncol; 2002 Feb; 24(2):84-5. PubMed ID: 11990709
    [No Abstract]   [Full Text] [Related]  

  • 12. Modulation of camptothecin analogs in the treatment of cancer: a review.
    Kehrer DF; Soepenberg O; Loos WJ; Verweij J; Sparreboom A
    Anticancer Drugs; 2001 Feb; 12(2):89-105. PubMed ID: 11261892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical studies of camptothecin and derivatives.
    Soepenberg O; Sparreboom A; Verweij J
    Alkaloids Chem Biol; 2003; 60():1-50. PubMed ID: 14593855
    [No Abstract]   [Full Text] [Related]  

  • 14. Camptothecins in clinical development.
    Zunino F; Pratesi G
    Expert Opin Investig Drugs; 2004 Mar; 13(3):269-84. PubMed ID: 15013945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A symphony for the camptothecins].
    Lansiaux A; Bailly C
    Bull Cancer; 2003 Mar; 90(3):239-45. PubMed ID: 12801826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topoisomerase I inhibition: a new target or new missiles?
    Verweij J; Schellens JH
    Ann Oncol; 1995 Feb; 6(2):102-4. PubMed ID: 7786815
    [No Abstract]   [Full Text] [Related]  

  • 17. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice.
    Kumazawa E; Jimbo T; Ochi Y; Tohgo A
    Cancer Chemother Pharmacol; 1998; 42(3):210-20. PubMed ID: 9685056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topoisomerase I inhibitors in the treatment of colorectal cancer.
    Rothenberg ML; Blanke CD
    Semin Oncol; 1999 Dec; 26(6):632-9. PubMed ID: 10606256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
    Garcia-Carbonero R; Supko JG
    Clin Cancer Res; 2002 Mar; 8(3):641-61. PubMed ID: 11895891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.
    Herben VM; Ten Bokkel Huinink WW; Schellens JH; Beijnen JH
    Pharm World Sci; 1998 Aug; 20(4):161-72. PubMed ID: 9762728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.